Profile data is unavailable for this security.
About the company
Corline Biomedical AB is a Sweden-based biotechnology company. It develops, manufactures and markets heparin-based solutions to improve kidney transplantation, cell therapies and applications in regenerative medicine.
- Revenue in SEK (TTM)7.65m
- Net income in SEK-14.71m
- Incorporated1991
- Employees12.00
- LocationCorline Biomedical ABLefflersgatan 5UPPSALA 75450SwedenSWE
- Phone+46 1 871346946
- Fax+46 18713091
- Websitehttps://www.corline.se/home
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elicera Therapeutics AB | 10.86m | -17.41m | 299.46m | 2.00 | -- | 12.82 | -- | 27.59 | -0.4128 | -0.4128 | 0.2696 | 0.4813 | 0.3948 | -- | 5.80 | 5,427,590.00 | -63.31 | -46.13 | -78.88 | -59.33 | -- | -- | -160.35 | -270.46 | -- | -- | -- | -- | 52.28 | -- | -8.05 | -- | -- | -- |
| Lipum AB (publ) | 0.00 | -76.37m | 307.58m | 6.00 | -- | -- | -- | -- | -3.60 | -3.60 | 0.00 | -1.33 | 0.00 | -- | -- | 0.00 | -179.79 | -146.87 | -660.20 | -220.28 | -- | -- | -- | -1,379,275.00 | -- | -39.82 | 3.77 | -- | -- | -- | -49.32 | -- | -- | -- |
| Biohit Oyj | 167.48m | 28.80m | 323.34m | 46.00 | 13.95 | 2.53 | 8.91 | 1.93 | 0.1778 | 0.1778 | 1.03 | 0.9804 | 0.8895 | 5.36 | 4.61 | 341,304.30 | 15.86 | 9.67 | 19.52 | 12.32 | 68.79 | 65.69 | 17.83 | 9.82 | 2.31 | -- | 0.097 | 0.00 | 9.92 | 17.12 | 5.14 | -- | 109.13 | -- |
| Corline Biomedical AB | 7.65m | -14.71m | 405.97m | 12.00 | -- | 4.33 | -- | 53.06 | -0.5929 | -0.5929 | 0.3093 | 3.66 | 0.0792 | -- | 5.89 | 637,583.30 | -15.22 | -9.29 | -16.29 | -10.07 | 81.36 | 109.32 | -192.31 | -60.64 | -- | -- | -- | -- | -21.73 | 15.66 | 36.56 | -- | -35.49 | -- |
| Enzymatica AB (publ) | 53.90m | -51.89m | 475.76m | 20.00 | -- | 3.83 | -- | 8.83 | -0.2138 | -0.2138 | 0.2221 | 0.5116 | 0.3197 | 1.17 | 4.88 | 2,695,150.00 | -30.78 | -33.41 | -33.37 | -38.75 | 61.45 | 61.39 | -96.27 | -104.78 | -- | -108.60 | 0.0082 | -- | 18.27 | -13.49 | 2.42 | -- | -45.57 | -- |
| Navamedic ASA | 536.68m | -22.34m | 498.55m | 45.00 | -- | 1.57 | 67.18 | 0.929 | -1.11 | -1.11 | 26.97 | 13.93 | 0.9351 | 3.48 | 8.28 | -- | -3.89 | -0.5784 | -5.27 | -0.8691 | 38.97 | 39.81 | -4.16 | -0.5578 | 0.887 | 0.4484 | 0.384 | -- | 6.38 | 21.92 | -329.13 | -- | -- | -- |
| Moberg Pharma AB (publ) | 13.54m | -27.24m | 504.17m | 5.00 | -- | 0.7313 | -- | 37.24 | -0.5809 | -0.5809 | 0.289 | 14.15 | 0.0195 | 1.49 | 4.58 | 2,707,600.00 | -3.92 | -11.42 | -4.02 | -11.95 | 56.73 | -- | -201.18 | -1,423.72 | 14.49 | -- | 0.0038 | -- | 37.99 | -- | 89.32 | -- | -- | -- |
| Dicot Pharma AB | 200.00k | -80.10m | 599.79m | 4.00 | -- | 8.17 | -- | 2,998.94 | -0.0416 | -0.0416 | 0.0001 | 0.0365 | 0.0019 | 10.77 | 0.0305 | -- | -76.61 | -87.67 | -86.56 | -101.98 | -35,950.00 | -32,362.81 | -40,050.00 | -36,853.27 | 6.40 | -- | -- | -- | 669.23 | 57.45 | -39.00 | -- | -- | -- |
Data as of Mar 02 2026. Currency figures normalised to Corline Biomedical AB's reporting currency: Swedish Krona SEK
0.02%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| FCG Fonder ABas of 31 Mar 2025 | 4.70k | 0.02% |
| Atle Fund Management ABas of 31 Dec 2024 | 0.00 | 0.00% |
Data from 30 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
